Pasar al contenido principal

RESISTENCIA MEDIADA POR EL MICROAMBIENTE EN GLIOBLASTOMA: CARACTERIZACION DE SU RELEVANCIA BIOLOGICA Y PROPUESTA DE APROXIMACIONES TERAPEUTICAS SINERGICAS

SAF2015-65175-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario INSTITUTO DE SALUD CARLOS III DE MADRID (ISCIII)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Oncogenic dependence of glioma cells on kish/TMEM167A regulation of vesicular trafficking

  • Portela, Marta
  • Segura-Collar, Berta
  • Argudo, Irene
  • Sáiz, Almudena
  • Gargini, Ricardo
  • Sánchez-Gómez, Pilar
  • Casas-Tinto, Sergio
Genetic lesions in glioblastoma (GB) include constitutive activation of PI3K and EGFR pathways to drive cellular proliferation and tumor malignancy. An RNAi genetic screen, performed in Drosophila melanogaster to discover new modulators of GB development, identified a member of the secretory pathway: kish/TMEM167A. Downregulation of kish/TMEM167A impaired fly and human glioma formation and growth, with no effect on normal glia. Glioma cells increased the number of recycling endosomes, and reduced the number of lysosomes. In addition, EGFR vesicular localization was primed toward recycling in glioma cells. kish/TMEM167A downregulation in gliomas restored endosomal system to a physiological state and altered lysosomal function, fueling EGFR toward degradation by the proteasome. These endosomal effects mirrored the endo/lysosomal response of glioma cells to Brefeldin A (BFA), but not the Golgi disruption and the ER collapse, which are associated with the undesirable toxicity of BFA in other cancers. Our results suggest that glioma growth depends on modifications of the vesicle transport system, reliant on kish/TMEM167A. Noncanonical genes in GB could be a key for future therapeutic strategies targeting EGFR-dependent gliomas., The authors would like to acknowledge Alberto Ferrús, Paco Martín,María Losada, and Elena Santana for critical comments on the manu-script. MP holds a fellowship from the Juan de la Cierva program IJCI-2014-19272 and SCT holds a contract from the Ramón y Cajal pro-gram RYC 2012-11410 from the Spanish MICINN. R.G. has beenfunded by the AECC Scientific Foundation. Research has been fundedby grants from the Ministerio de Economía y Competitividad(MINECO-RETOS) SAF2015-65175-R to PSG and (MINECO-EXCE-LENCIA) BFU2015-65685P to SCT.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The EGFR-TMEM167A-p53 axis defines the aggressiveness of gliomas

  • Segura-Collar, Berta
  • Gargini, Ricardo
  • Tovar-Ambel, E.
  • Hernández-SanMiguel, Esther
  • Epifano, Carolina
  • De Castro, I.P.
  • Hernández-Laín, Aurelio
  • Casas-Tinto, Sergio
  • Sánchez-Gómez, Pilar
Despite the high frequency of EGFR and TP53 genetic alterations in gliomas, little is known about their crosstalk during tumor progression. Here, we described a mutually exclusive distribution between mutations in these two genes. We found that wild-type p53 gliomas are more aggressive than their mutant counterparts, probably because the former accumulate amplifications and/or mutations in EGFR and show a stronger activation of this receptor. In addition, we identified a series of genes associated with vesicular traffcking of EGFR in p53 wild-type gliomas. Among these genes, TMEM167A showed the strongest implication in overall survival in this group of tumors. In agreement with this observation, inhibition of TMEM167A expression impaired the subcutaneous and the intracranial growth of wild-type p53 gliomas, regardless of the presence of EGFR mutations. In the absence of p53 mutations, TMEM167A knockdown reduced the acidification of intracellular vesicles, a ecting the autophagy process and impairing EGFR traffcking and signaling. This e ect was mimicked by an inhibitor of the vacuolar ATPase. We propose that the increased aggressiveness of wild-type p53 gliomas might be due to the increase in growth factor signaling activity, which depends on the regulation of vesicular traffcking by TMEM167A., This research was funded by the Ministerio de Economía y Competitividad: (Acción Estratégica en Salud) grants: PI13/01258 to AHL; by “Asociación Española contra el Cancer” (AECC) grants: Junior Researcher to RG; and by Ministerio de Economía y Competitividad: SAF2015-65175-R/FEDER to PSG.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas

  • Gargini, Ricardo
  • Segura-Collar, Berta
  • Herranz, Beatriz
  • García-Escudero, Vega
  • Romero-Bravo, Andrés
  • Núñez, Felipe J.
  • García-Pérez, Daniel
  • Gutiérrez-Guamán, Jacqueline
  • Ayuso-Sacido, Angel
  • Seoane, Joan
  • Pérez-Núñez, Angel
  • Sepúlveda-Sánchez, Juan Manuel
  • Hernández-Laín, Aurelio
  • Castro, María G.
  • García-Escudero, Ramón
  • Ávila, Jesús
  • Sánchez-Gómez, Pilar
Gliomas that express the mutated isoforms of isocitrate dehydrogenase 1/2 (IDH1/2) have better prognosis than wild-type (wt) IDH1/2 gliomas. However, how these mutant (mut) proteins affect the tumor microenvironment is still a pending question. Here, we describe that the transcription of microtubule-associated protein TAU (MAPT), a gene that has been classically associated with neurodegenerative diseases, is epigenetically controlled by the balance between wt and mut IDH1/2 in mouse and human gliomas. In IDH1/2 mut tumors, we found high expression of TAU that decreased with tumor progression. Furthermore, MAPT was almost absent from tumors with epidermal growth factor receptor (EGFR) mutations, whereas its trancription negatively correlated with overall survival in gliomas carrying wt or amplified (amp) EGFR. We demonstrated that the overexpression of TAU, through the stabilization of microtubules, impaired the mesenchymal/pericyte-like transformation of glioma cells by blocking EGFR, nuclear factor kappa-light-chain-enhancer of activated B (NF-κB) and the transcriptional coactivator with PDZ-binding motif (TAZ). Our data also showed that mut EGFR induced a constitutive activation of this pathway, which was no longer sensitive to TAU. By inhibiting the transdifferentiation capacity of EGFRamp/wt tumor cells, TAU protein inhibited angiogenesis and favored vascular normalization, decreasing glioma aggressiveness and increasing their sensitivity to chemotherapy., This work was supported by NIH/ NINDS grants R01-NS105556 and R37-ND094804 to M.G.C.; by Ministerio de Economía y Competitividad (Acción Estratégica en Salud) grants PI13/01258 to A.H.-L., PI17/01489 and CP11/00147 to A.A.-S., PI18/00263 to R.G.-E., and PI16/01 278 to J.S.; by “Asociación Española contra el Cancer” grants Investigador Junior to R.G. and GCTRA16015SEDA to J.M.S.-S. and J.S.; and by Ministerio de Economía y Competitividad SAF-2014-53040-P to J.A., RTC-2015-3771-1 to J.S., and SAF2015-65175-R/FEDER to P.S.-G, Peer reviewed